Agarwal S., Jangir D.K., Mehrotra R. (2013) Spectroscopic studies of the effect of anticancer drug mitoxantrone interaction with calf thymus DNA. J. Photochem. Photobiol. B. 120: 177-182.
Aivasashvilli V.A. and Beabealashvilli, R.S. (1983) Sequence-specific inhibition of RNA elongation by actinomycin D. FEBS Lett., 160: 124–128.
Bradbury E.M., Van Hold K. (2004) Chromatin structure and dynamics: a historical perspective. New Compr Biochem. 39:1-11
Burgoyne L.A., Wagar M.A., Atkinson M.R. (1970) Calcium-dependent priming of DNA synthesis in isolated rat liver nuclei. Biochem. Biophys. Res. Commun., 39: 254-259.
Cesconetto E.C., Junior F.C., Crisafuli F.A., Mesquita O.N., Ramos E.B., Rocha, M.S. (2013) Dna interaction with actinomycin D: mechanical measurements reveal the details of the binding data. Phy. Chem. Che. Pys. 15: 11070-11077.
Chan A., Lo-Coco F. (2013) Mitoxantrone-related acute leukemia in MS: an open or closed book. Neurology 80: 1529-1533.
Faulds D., Balfour J.A., Chrisp P., Langtry H.D. (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs., 41(3): 400-49.
Freifelder D.M. (1982) Physical Biochemistry. 2nd edition., chapter 15,.W.H. Freeman,Inc. pp 537-572., NewYork.
Hajihassan Z., Rabbani-Chadegani A. (2009) Studies on the binding affinity of anticancer drug mitoxantrone to chromatin, DNA and histone proteins. J. Biomed. Sci. 16(1): 31.
Hajihassan Z., Rabbani-Chadegani A. (2011) Interaction of mitoxantrone as an anticancer drug with chromatin proteins, Core hitone and H1 in solution. Int. J. Biol. Macromol. 48: 87-92.
Koba M., Konopa J. (2005) Actinomycin D and its mechanisms of action. Postepy Hig. Med. Dosw. 59: 290-298.
Laemmli U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature., 227: 680-685.
Lewis J.L. (1972) Chemotherapy of gestational choriocarcinoma, Cancer. 30: 1517–1521.
Li N., Ma Y., Yang C., Guo L., Yang X. (2005) Interaction of anticancer drug mitoxantrone with DNA analyzed by electrochemical and spectroscopic methods. Biophys. Chem. 116: 199-205.
Liu X., Chen H., Patel D.J. (1991) Solution structure of actinomycin-DNA complexes: drug intercalation at isolated G-C sites. J. Biomol. NMR. 1(4): 323-47.
Lown J.W., Morgen A.R., Yen S.F., Wang Y.H. and Wilson D.W. (1985) Characteristics of the binding of the anticancer agent's mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry., 24: 4028-4035.
Nishio A., Uveki E.M. (1983) Cellular uptake and inhibition of DNA synthesis by dihydroxy anthraquinone and two analogues. Cancer.Res., 43(5): 1951-1956.
Ory S., Debouverie M., Le Page E., Pelletier J., Malikova I., Gout O., Edan G. (2008) Use of mitoxantrone in early Multiple Sclerosis with malignant disease course. Observational study in 30 patients with clinical and MRI outcomes after one year. Rev.Neurol (Paris)., 164(12): 1028-1034.
Rabbani A., Iskander M., Ausio J. (1999) Daunomycin-induced unfolding and aggregation of chromatin. J. Biol. Chem., 274: 18401-18406.
Rapkin L.M., Anchel D.R., Li R., Bazell-Jones D.P. (2012) A view of the chromatin landscape. Micron 43: 150-158.
Rosenberg L.S., Carvlin M.J., Krugh T.R. (1986) The antitumor agent mitoxantrone binds cooperatively to DNA: Evidence for heterogeneity in DNA conformation. Biochemistry., 25: 1002-1008.
Scatchard G. (1949) The attraction of proteins for small molecules and ions. Ann.N.Y.Acad.Sci., 51: 660-672.
Scott L.J., Figgitt D.P. (2004) Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs 18: 379-396.
Sha F., Chen F.M. (2000) Actinomycin D Binds Strongly to d (CGACGACG) and d(CGTCGTCG). Biophys. J. 79(4): 2095-2104.
Snyder J.G., Hartman N.G., D'Estantoit B.L., Kennard O., Remeta D.P., Breslauer K.J. (1989) Binding of actinomycin D to DNA: evidence for a nonclassical high-affinity binding mode that does not require GpC sites. Proc. Natl. Acad .Sci. U S A., 86(11): 3968-72.